Home » Healthcare » Pharmaceuticals » Premature Ejaculation Treatment Market

Premature Ejaculation Treatment Market By Drug Class (Selective Serotonin Reuptake Inhibitor, Tricyclic Antidepressant, Topical Anesthetic Agent, Phosphodiesterase Type 5 Inhibitors, Others), By Route Of Administration (Oral Route, Topical Route) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Market Synopsis

The premature ejaculation treatment market is expected to reach US$ 3,541.4 million by 2026, up from US$ 1,666.1 million in 2017, with a compound annual growth rate (CAGR) of 8.8% from 2018 to 2026. According to the research survey conducted by the International Journal of Impotence Research (IJIR), 30% of adult men throughout the globe suffer from premature ejaculation. The prevalence rate of premature ejaculation varies across geographical and sociocultural populations. Premature ejaculation has been understood to have a negative impact on the sexual satisfaction of men and their sexual partners.

People suffering from premature ejaculation are less likely to seek medical help, thus making it of utmost importance to raise awareness and acceptance of this disorder among patients and physicians. The existence of developed healthcare infrastructure and the rising prevalence of premature ejaculation disorder drive the market’s growth in North America. The presence of a mature generic drug market and increasing awareness of premature ejaculation propel the market’s growth in Asia-Pacific.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Impressive pharmacodynamic properties exerted by SSRIs make them the drug of the first choice for premature ejaculation treatment.

Selective serotonin reuptake inhibitors are prescribed as the first-line drug therapy for the treatment of premature ejaculation. The mechanism of action is delayed ejaculation due to limited serotonin reabsorption at presynaptic neuron cells and increased serotonin levels at postsynaptic receptors. The drugs prescribed as SSRIs are sertraline, paroxetine, fluoxetine, and citalopram. Topical anesthetic agents are set to project impressive growth during the forecast period of 2018 to 2026. Currently, FortacinTM, a eutectic mixture of Lidocaine and Prilocaine, is being used as a topical aerosol formulation to decrease the sensitivity of the glans penis and increase the intravaginal ejaculation latency time. The topical anesthetic agents have better patient compliance and excellent sexual satisfaction in patients suffering from premature ejaculation.

Faster onset of action and a low price make the oral route of administration popular among patients suffering from acute premature ejaculation.

Prescribed drugs such as SSRIs, tricyclic antidepressants, phosphodiesterase type 5 inhibitors, and beta-adrenergic blockers are taken by the oral route of administration. Quick response time and availability at a low price increase the popularity of the oral route among patients suffering from acute premature ejaculation. The topical route is to register magnificent growth during the forecast period of 2018–2026 due to better patient compliance and excellent climax control by delaying intravaginal ejaculation.

The rise in psychotropic drug use and a negative attitude toward sex drive Asia-Pacific market growth.

In the present scenario, North America holds the largest regional market in the premature ejaculation treatment market, with a 41.5% share. The rising incidence of relationship stress, depression, and anxiety in the younger population and the increasing number of people suffering from illicit drug abuse is responsible for premature ejaculation issues in North America. The domicile of market leaders such as GlaxoSmithKline Plc and Teva Pharmaceutical Industries Ltd. and adherence to effective treatment guidelines drive the premature ejaculation treatment market in Europe. Asia-Pacific serves as a lucrative market for premature ejaculation treatment. The factors responsible for the market’s growth are the rise in psychotropic drug use and the lack of a constructive attitude towards sex. Latin America, the Middle East, and Africa will project moderate growth during the forecast period of 2018–2026 on account of developing healthcare infrastructure and rising public health awareness regarding premature ejaculation.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026,considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The latest market trends for the premature ejaculation treatment market were determined by quantitative analysis. The market segment comprises drug class, route of administration, and geography.

The premature ejaculation market comprises branded and generic drugs, which are prescribed according to the disease prognosis. Inorganic and organic market growth strategies are being employed by market leaders to generate revenue in the premature ejaculation treatment market. Quantitative analysis is a very useful tool for mapping the drivers, restraints, and opportunities prevalent in the premature ejaculation treatment market. A diverse product portfolio gives a better understanding of the competition prevalent in the market. The pharmaceutical companies commanding the premature ejaculation treatment market are Absorption Pharmaceuticals, AstraZeneca, Allergan Plc, Bayer AG, Eli Lilly & Company, GlaxoSmithKline Plc, Innovus Pharmaceuticals, Merck & Co., Inc., Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

Who are the market leaders steering the premature ejaculation treatment market?
What will be the compound annual growth rate and market estimation for the premature ejaculation treatment market?
What are the organic and inorganic market strategies adopted by key players?
What are the DROs for the premature ejaculation treatment market?
What is the disease prognosis, and how does it contribute to market growth?
Which is the leading and fastest-growing route of administration segment for the premature ejaculation treatment market?
Which is the largest and fastest-growing drug class segment for the premature ejaculation treatment market?
Which is the largest and fastest-growing regional segment for the premature ejaculation treatment market?
What drugs are being prescribed, and what treatment guidelines are postulated for the treatment of premature ejaculation?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global PET Market Portraiture
2.2. Global PET Market, by Drug Class, 2017 (US$ Mn)
2.3. Global PET Market, by Route of Administration, 2017 (US$ Mn)
2.4. Global PET Market, by Geography, 2017 (US$ Mn)

Chapter 3. Premature Ejaculation Treatment (PET) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global PET Market, by Key Players, 2017

Chapter 4. Global Premature Ejaculation Treatment (PET) Market, by Drug Class
4.1. Overview
4.2. Selective Serotonin Reuptake Inhibitor
4.2.1. Paroxetine
4.2.2. Sertraline
4.2.3. Citalopram
4.2.4. Fluoxetine
4.3. Tricyclic Antidepressant
4.3.1. Clomipramine
4.4. Topical Anesthetic Agent
4.4.1. Lidocaine/Prilocaine
4.4.2. Benzocaine
4.5. Phosphodiesterase Type 5 Inhibitors
4.5.1. Sildenafil
4.5.2. Vardenafil
4.6. Others (Beta-adrenergic Blockers, Analgesic Opioids)

Chapter 5. Global Premature Ejaculation Treatment (PET) Market, by Route of Administration
5.1. Overview
5.2. Oral Route
5.3. Topical Route

Chapter 6. Global Premature Ejaculation Treatment (PET) Market, by Geography
6.1. Overview
6.2. North America PET Market Analysis, 2016 – 2026
6.2.1. North America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.2.2. North America PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.2.3. North America PET Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe PET Market Analysis, 2016 – 2026
6.3.1. Europe PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.3.2. Europe PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.3.3. Europe PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Premature Ejaculation Treatment Drugs Market Analysis, 2016 – 2026
6.4.1. Asia Pacific PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America PET Market Analysis, 2016 – 2026
6.5.1. Latin America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.5.2. Latin America PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.5.3. Latin America PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa PET Market Analysis, 2016 – 2026
6.6.1. MEA PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.6.2. MEA PET Market, by ROA, 2016 – 2026 (US$ Mn)
6.6.3. MEA PET Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Absorption Pharmaceuticals
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. AstraZeneca
7.3. Allergan, Plc
7.4. Bayer AG
7.5. Eli Lilly & Company
7.6. GlaxoSmithkline, Plc
7.7. Innovus Pharmaceutical
7.8. Merck & Co., Inc.
7.9. Pfizer, Inc.
7.10. Teva Pharmaceutical Industries Ltd.

List of Figures

FIG. 1 Premature Ejaculation Treatment (PET) Market: Research Methodology
FIG. 2 PET Market Segmentation
FIG. 3 Global PET Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global PET Market, by ROA, 2017 (US$ Mn)
FIG. 5 Global PET Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global PET Market, by Key Players, 2017
FIG. 8 Global Paroxetine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 9 Global Sertraline Market for PET, 2016 – 2026 (US$ Mn)
FIG. 10 Global Citalopram Market for PET, 2016 – 2026 (US$ Mn)
FIG. 11 Global Fluoxetine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 12 Global Tricyclic Antidepressant Market for PET, 2016 – 2026 (US$ Mn)
FIG. 13 Global Lidocaine/Prilocaine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 14 Global Benzocaine Market for PET, 2016 – 2026 (US$ Mn)
FIG. 15 Global Sildenafil Market for PET, 2016 – 2026 (US$ Mn)
FIG. 16 Global Vardenafil Market for PET, 2016 – 2026 (US$ Mn)
FIG. 17 Global Other Drug Class Market for PET, 2016 – 2026 (US$ Mn)
FIG. 18 Global Oral Route Market for PET, 2016 – 2026 (US$ Mn)
FIG. 19 Global Topical Route Market for PET, 2016 – 2026 (US$ Mn)
FIG. 20 U.S. PET Market, 2016 – 2026 (US$ Mn)
FIG. 21 Canada PET Market, 2016 – 2026 (US$ Mn)
FIG. 22 U.K. PET Market, 2016 – 2026 (US$ Mn)
FIG. 23 Germany PET Market, 2016 – 2026 (US$ Mn)
FIG. 24 Rest of Europe PET Market, 2016 – 2026 (US$ Mn)
FIG. 25 China PET Market, 2016 – 2026 (US$ Mn)
FIG. 26 Japan PET Market, 2016 – 2026 (US$ Mn)
FIG. 27 Rest of Asia Pacific PET Market, 2016 – 2026 (US$ Mn)
FIG. 28 Brazil PET Market, 2016 – 2026 (US$ Mn)
FIG. 29 Mexico PET Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest of Latin America PET Market, 2016 – 2026 (US$ Mn)
FIG. 31 GCC PET Market, 2016 – 2026 (US$ Mn)
FIG. 32 Rest of Middle East and Africa PET Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Premature Ejaculation Treatment (PET) Market Portraiture
TABLE 2 Global PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global SSRI Market for PET, by Drug Class, 2017 (US$ Mn)
TABLE 4 Global Topical Anesthetic Agents Market for PET, by Drug Class, 2017 (US$ Mn)
TABLE 5 Global Phosphodiesterase Type 5 Inhibitors Market for PET, by Drug Class, 2017 (US$ Mn)
TABLE 6 Global PET Market , by ROA, 2016 – 2026 (US$ Mn)
TABLE 7 Global PET Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 North America PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 10 North America PET Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 11 Europe PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 12 Europe PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 13 Europe PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Asia Pacific PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 16 Asia Pacific PET Market, by Country/Region, 2015 – 2025 (US$ Mn)
TABLE 17 Latin America PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 18 Latin America PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 19 Latin America PET Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 Middle East and Africa PET Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 21 Middle East and Africa PET Market, by ROA, 2016 – 2026 (US$ Mn)
TABLE 22 Middle East and Africa PET Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 23 Absorption Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 AstraZeneca: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Allergan, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 GlaxoSmithkline, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Innovus Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Question

What is the size of Premature Ejaculation Treatment Market?

The market for Premature Ejaculation Treatment Market is expected to reach USD$ 3,541.4 Mn in 2026.

What is the Premature Ejaculation Treatment Market CAGR?

The Premature Ejaculation Treatment Market is expected to see significant CAGR growth over the coming years, at 8.8%.

What is the Forecast period considered for Premature Ejaculation Treatment Market?

The report is forecasted from 2018 -2026.

What is the base year considered for Premature Ejaculation Treatment Market?

The base year of this report is 2017.

Who are the major players in this market?

BAllergan Plc, Bayer AG, Eli Lilly & Company, GlaxoSmithKline Plc, Innovus Pharmaceuticals, Merck & Co., Inc., Pfizer, Inc. are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –